PharmaShots | Incisive News in 3 Shots

Subscribe Now

sellas

SELLAS Reports Data from Preclinical Studies Suggesting ASXL1 Mutations as Predictor of SLS009 Response in Solid Tumors

SELLAS Reports Data from Preclinical Studies Suggesting ASXL1 Mutations as Predictor of SLS009 Response in Solid Tumors

November 29, 2024

SELLAS Reports Results for SLS009 in P-IIa Trial for the Treatment of Acute Myeloid Leukemia (AML)

SELLAS Reports Results for SLS009 in P-IIa Trial for the Treatment of Acute Myeloid Leukemia (AML)

March 27, 2024

PharmaShots Weekly Snapshots (October 09–13, 2023) _

PharmaShots Weekly Snapshots (October 09–13, 2023) _

October 14, 2023

SELLAS Receives the US FDA’s Orphan Drug Designation to SLS009 for the Treatment of Acute Myeloid Leukemia

SELLAS Receives the US FDA’s Orphan Drug Designation to SLS009 for the Treatment of Acute Myeloid Leukemia

October 12, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us